- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05261516
Interaction of Volatile Anesthetics With Magnesium (Volmag)
Interaction Between Intravenous Magnesium Sulfate and Volatile Anesthetics Compared to Propofol. A Three-center Prospective Randomized Single-blinded Electrophysiological Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Magnesium sulfate is regularly used during anesthesia, for instance for the reduction of postoperative pain. It reduces the liberation of acetylcholine at the neuromuscular junction. At high plasma concentrations it can induce muscle weakness, flaccid paralysis and in cases of intoxication lead to respiratory arrest. It enhances the effect of muscle relaxants.
Volatiles anesthetics influence neuromuscular transmission. They inhibit postsynaptic nicotinic acetylcholine receptors by causing open channel block, receptor desensitization and reducing exocytosis from pre-synaptic vesicles at the neuromuscular junction. The ranking order of these effects of volatile anesthetics on neuromuscular transmission is: desflurane > sevoflurane > isoflurane, depending on their blood-gas and tissue-gas solubility index.
Magnesium given intravenously during volatile anesthesia induces effects on neuromuscular transmission similar to that of neuromuscular blocking agents. This effect has never been investigated and quantified systematically and prospectively.
Propofol, an intravenous anesthetic, has very little effects on neuromuscular transmission. Therefore magnesium given intravenously during total intravenous anesthesia with propofol has no or only very little effect on neuromuscular transmission.
The primary objective of the study is to quantify the effect of a perfusion of intravenous magnesium on neuromuscular transmission measured by accelerometry with theTetraGraph device in patients undergoing general anesthesia with volatile anesthetics (desflurane, sevoflurane and isoflurane) as compared to intravenous anesthesia with propofol. The investigators expect a following rank order of the effect: desflurane > sevoflurane > isoflurane > propofol.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sina Grape, MD, MBA
- Phone Number: 0041276038759
- Email: sina.grape@hopitalvs.ch
Study Contact Backup
- Name: Christoph Czarnetzki, MD, MBA
- Phone Number: +41 091 8116664
- Email: christoph.czarnetzki@hcuge.ch
Study Locations
-
-
-
Sion, Switzerland, 1951
- Recruiting
- Department of Anesthesiology and Intensive Care, Valais Hospital
-
Contact:
- Sina Grape, MD, MBA
- Email: sina.grape@hopitalvs.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients, age 18 to 65 years inclusive
- American Society of Anesthesiology [ASA] status I or II
- Body mass index 19 - 30 kg/m2
- Patient scheduled for elective surgery lasting ≥ 60 minutes
- Patient is able to read and understand the information sheet and to sign and date the consent form.
- Negative urinary or serum pregnancy test (not applicable if status post hysterectomy or tubal ligation or menopausal woman)
Exclusion Criteria:
- Surgery with need for neuromuscular block
- Contraindication for general anesthesia with laryngeal mask airway, such as gastro-oesophageal reflux.
- Hypersensitivity or allergy to magnesium sulfate or propofol
- Contraindication to volatile anesthetics such as malignant hyperthermia
- Patients with neuromuscular disease
- Patients receiving medications known to influence neuromuscular function (for instance, aminoglycosides or phenytoine)
- Known electrolyte abnormalities (for instance, hypermagnesemia)
- Atrioventricular heart block
- Patients with magnesium treatment within 48 hours before start of study
- Liver insufficiency (bilirubine <1.5x, ALAT/ASAT<2.5x the upper limit of normal value)
- Renal insuffisancy (créatinine <1.5x upper limit of normal value, clearance<30ml/minute)
- Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial.
- Pregnant or breast-feeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Propofol
In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. In patients in the propofol group, anesthesia will be induced and maintained with a total intravenous anesthesia pump following the model of Schnider et al, at a targeted effect-site concentration of 4 +/- 1 mcg/ml. In patients in all groups, after induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital. |
The experimental intervention is the injection of magnesium sulfate.
This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable.
Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes.
Vital signs before, during and after the perfusion will be taken and documented.
|
Experimental: Isoflurane
In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital. The anesthesia will be maintained with the agent specified by randomization: isoflurane in this group. |
The experimental intervention is the injection of magnesium sulfate.
This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable.
Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes.
Vital signs before, during and after the perfusion will be taken and documented.
|
Experimental: Desflurane
In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital. The anesthesia will be maintained with the agent specified by randomization: desflurane in this group. |
The experimental intervention is the injection of magnesium sulfate.
This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable.
Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes.
Vital signs before, during and after the perfusion will be taken and documented.
|
Experimental: Sevoflurane
In all patients 3 minutes before induction sufentanil 0.2 mcg/kg or fentanyl 2 mcg/kg will be given. After induction of anesthesia and loss of consciousness, a laryngeal mask airway will be inserted. The TetraGraph device will be calibrated. Once general anesthesia is established, a blood sample will be taken to measure serum magnesium and calcium levels. This blood sample will be analysed in the certified laboratory of each participating hospital. The anesthesia will be maintained with the agent specified by randomization: sevoflurane in this group. |
The experimental intervention is the injection of magnesium sulfate.
This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable.
Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes.
Vital signs before, during and after the perfusion will be taken and documented.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in TOF ratio after perfusion of magnesium
Time Frame: After starting TOF AUTO mode. patients will receive an intravenous perfusion of magnesium 60mg/kg mg kg-1 over 5 minutes. Neuromuscular monitoring will be continued until the end of surgery, but at least until a TOF ratio of 0.9 is reached.
|
This primary outcome will be assessed with neuromuscular monitoring, carried out according to international guidelines.
The ulnar nerve will be stimulated by train-of-four (TOF) using a TofScan monitor.
|
After starting TOF AUTO mode. patients will receive an intravenous perfusion of magnesium 60mg/kg mg kg-1 over 5 minutes. Neuromuscular monitoring will be continued until the end of surgery, but at least until a TOF ratio of 0.9 is reached.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lowest T1 twitch height and TOF ratio
Time Frame: After the perfusion of magnesium and until the T1 twitch height and the TOF ratio reach the initial values again.
|
The secondary outcomes are the lowest T1 twitch height and TOF ratio measured after starting the magnesium perfusion and the time required for the return of single twitch height (T1) and TOF ratio to its control value according to the TofScan measurements.
|
After the perfusion of magnesium and until the T1 twitch height and the TOF ratio reach the initial values again.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Magnesium Sulfate
Other Study ID Numbers
- 2019-02104/CE3541
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Blockade
-
Hospital Federal de BonsucessoUnknownNeuromuscular Blockade | Magnesium Sulfate | Rocuronium | Deep Neuromuscular BlockadeBrazil
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedNeuromuscular Blockade | Neuromuscular MonitoringItaly
-
Universitair Ziekenhuis BrusselUnknownNeuromuscular Blockade | Neuromuscular MonitoringBelgium
-
Matias VestedNot yet recruitingNeuromuscular BlockadeDenmark
-
Central Hospital, Nancy, FranceNot yet recruitingComparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function (DECURAR-EMG)Neuromuscular BlockadeFrance
-
Vanderbilt University Medical CenterUniversity of Pittsburgh; The Cooper Health SystemRecruitingNeuromuscular BlockadeUnited States
-
Leiden University Medical CenterMerck Sharp & Dohme LLCCompletedNeuromuscular BlockadeNetherlands
-
Seoul National University Bundang HospitalCompleted
-
Poitiers University HospitalEnrolling by invitationNeuromuscular BlockadeFrance
-
Centre Hospitalier Universitaire Dinant Godinne...CompletedNeuromuscular BlockadeBelgium
Clinical Trials on Magnesium Sulfate
-
Aurora Health CareNot yet recruitingAtrial Fibrillation | Tachycardia Atrial | Atrial Flutter With Rapid Ventricular ResponseUnited States
-
University of OklahomaRecruitingAsthma in Children | Asthma AttackUnited States
-
Sohag UniversityRecruitingPost Operative Pain, AcuteEgypt
-
Thomas Jefferson UniversityNot yet recruiting
-
Margaux M. Salas, PhDNot yet recruitingPTSD | Neuropathic Pain
-
Sohag UniversityCompletedPersistent Pulmonary Hypertension of the Newborn | PPHN | Persistent Fetal CirculationEgypt
-
Instituto Materno Infantil Prof. Fernando FigueiraCompletedSevere PreeclampsiaBrazil
-
Queen Sirikit National Institute of Child HealthUnknownAcute Severe AsthmaThailand
-
Assiut UniversityCompletedMaternal Care PatternsEgypt
-
Assiut UniversityRecruitingIntracranial Pressure Control in Pre-eclampsiaEgypt